Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2009 Results
Date:4/29/2009

Circadian Rhythm Sleep Disorders.

FINANCIAL DETAILS

* Operating Expenses. First quarter 2009 R&D expenses of $2.3 million,

consisted primarily of $0.5 million of salaries and benefits and

$0.2 million of non-cash stock based compensation costs for R&D

personnel, as well as $0.8 million of regulatory consultant fees,

and $0.2 million of pre-clinical work. This compares to

$3.6 million for the fourth quarter of 2008 and $11.1 million for

the first quarter of 2008. The decrease in R&D expenses in the first

quarter of 2009 relative to the fourth quarter of 2008 is primarily

due to the decrease in regulatory consulting and other professional

fees related to iloperidone. The decrease in R&D expenses in the

first quarter of 2009 relative to the first quarter of 2008 is

primarily due to the completion in the second quarter of 2008 of the

Phase III clinical trial for tasimelteon in chronic primary

insomnia.

General and administrative (G&A) expenses of $4.2 million for the

first quarter of 2009 consisted primarily of $0.5 million of

salaries and benefits and $2.1 million of non-cash stock based

compensation costs for G&A personnel, as well as $0.7 million of

legal fees, and $0.2 million of insurance costs. This compares to

$4.1 million for the fourth quarter of 2008 and $9.0 million for the

first quarter of 2008. The increase in G&A expenses in the first

quarter of 2009 relative to the fourth quarter of 2008 is primarily

due to an increase in legal and professional fees offset by a

decrease in stock-based compensation costs. The decrease in
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
2. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
3. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
6. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
8. Onyx Pharmaceuticals Announces First Quarter 2009 Financial Results Teleconference and Webcast
9. Transcept Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
10. Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator
11. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 Research and Markets ( ... "Global Bioinformatics Market Outlook 2019" report to their ... mark of around US$ 3.7 Billion in 2013 with ... around 19% during 2015-2019 The report is ... of global developments and opportunities listed in the section ...
(Date:4/21/2015)... 21, 2015 Research and Markets ... the "Complete 2015-16 Induced Pluripotent Stem Cell ... Stem cell research and experimentation have ... as stem cells have the unique ability to ... nature allows them to differentiate into a wide ...
(Date:4/21/2015)... , April 21, 2015 The ... $313.0 million in 2014 to $605.1 million by 2019, at ... Browse through the TOC of ... analysis of the industry trends and segments, with help ... Early buyers will receive 10% ...
(Date:4/21/2015)... Contract Research Organization XenoTech, LLC , a division of ... ft2 facility. The planned move will double the size ... St. in Lenexa, KS. The new facility, boasting nearly ... remain in the Kansas City metro area, just blocks away ... ago. Remaining in the Kansas City area maintains the ...
Breaking Biology Technology:Global Bioinformatics Market Outlook Report 2014-2019 - The US$ 3.7 Billion Market is Expected to Grow at a CAGR of 19% during 2015-2019 2Global Bioinformatics Market Outlook Report 2014-2019 - The US$ 3.7 Billion Market is Expected to Grow at a CAGR of 19% during 2015-2019 3Global Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report 2North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 2North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 3XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 2XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 3
... Sept. 19 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. ... CSKI ), a,leading fully integrated pharmaceutical company ... ("PRC"), announced today that it,has successfully completed the ... certification, or CE mark, which indicates that,a company,s ...
... seven medical,experts in psychiatry from across the world ... action to optimize services for people with a,diagnosis ... bipolar,disorder(i)., Professor W. Wolfgang Fleischhacker, principal author ... Disorders: Clinical,Policy, and Research Challenges which was published ...
... MedNet Solutions, a global,eClinical technology company specializing ... active involvement as a speaker,sponsor and exhibitor at ... Conference, to be held Sunday, September 21 through,Wednesday, ... has invited Dr. Timothy Pratt, PhD, Chief Marketing ...
Cached Biology Technology:China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification 2China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification 3Global Psychiatrists Unite to Improve Services in Mental Health 2Global Psychiatrists Unite to Improve Services in Mental Health 3MedNet Solutions to Speak, Sponsor and Exhibit at the 2008 Society of Clinical Data Management Annual Conference in Dallas 2
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
(Date:4/17/2015)... , April 17, 2015 ... security concerns, and technological advancement to drive biometric ... until 2020   According to ... Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market ... projected to register growth at CAGR of over ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... to double the odds a teenage girl will begin smoking, ... who analyzed the dieting and smoking practices of 8,000 adolescents, ... also less likely than girls to diet, according to findings ... Dieting was a significant predictor of initiation of regular smoking ...
... 2007- As of late, many uncertainties have been sprouting ... wondering if precision agricultural technologies can improve crop yield ... asking a number of questions from, which hybrid should ... applying nitrogen fertilizer at a uniform rate produce a ...
... Chicago researchers have identified new sites on the ... delivered to treat infections. "The primary challenge ... by the pathogens which became resistant to antibiotics," ... UIC,s Center for Pharmaceutical Biotechnology and lead investigator ...
Cached Biology News:Girls who begin dieting twice as likely to start smoking 2Girls who begin dieting twice as likely to start smoking 3The 5 Ws of corn production 2UIC researchers find promising new targets for antibiotics 2
Recombinant Mouse Noggin...
PEG 8000 is used in the precipitation of phage, isolation of plasmid DNA and the enhancement of blunt-ended ligation reactions....
Human VASA Biotinylated Affinity Purified PAb...
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Biology Products: